人民财讯1月25日电，方盛制药（603998）1月25日公告，1月23日，公司全资子公司健盟药业收到国家 药品监督管理局核准签发的《药品注册证书》，洛索洛芬钠凝胶贴膏已获得药品批准文号并可进行生 产。洛索洛芬钠凝胶贴膏适用于骨关节炎、肌肉痛及外伤后的肿胀疼痛的消炎、镇痛，有效成分为洛索 洛芬钠，属苯丙酸类非甾体抗炎药(NSAID)，具有显著的抗炎镇痛作用，尤以镇痛效果为强。 ...

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 洛索洛芬钠凝胶贴膏适用于骨关节炎、肌肉痛及外伤后的肿 胀疼痛的消炎、镇痛，有效成分为洛索洛芬钠，属苯丙酸类非甾 第 1页，共 3页 药品名称 洛索洛芬钠凝胶贴膏 受理号 CYHS2402679 证书编号 2026S00080 主要成分 洛索洛芬钠 剂型 贴膏剂 申请事项 药品注册（境内生产） 规格 每贴（14cm×10cm）含膏体 10g，含洛索洛芬钠 100mg（按 C15H17NaO3计） 注册分类 化学药品 4 类 药品注册标准编号 YBH34292025 药品批准文号 国药准字 H20263068 药品批准文号有效期 至 2031 年 1 月 13 日 上市许可持有人 广东方盛健盟药业有限公司 生产企业 湖南方盛制药股份有限公司 审批结论 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 一、《药品注册证书》主要内容 证券代码：603998 证券简称：方盛制药 公告编号：2026-005 湖南方盛制药股份有限公司 关于洛索洛芬钠凝胶贴膏获得《 ...

每经AI快讯，方盛制药1月25日晚间发布公告称，2026年1月23日，湖南方盛制药股份有限公司全资子 公司广东方盛健盟药业有限公司收到国家药品监督管理局核准签发的《药品注册证书》，洛索洛芬钠凝 胶贴膏已获得药品批准文号并可进行生产。 每经头条（nbdtoutiao）——丹麦士兵荷枪实弹上岛，准备战斗！反击特朗普夺岛图谋，美最大债主3.6 万亿美元"金融核弹"可随时引爆，格陵兰风云骤起 （记者 王晓波） ...

2026年1月22日 湖南方盛制药股份有限公司（以下简称"公司"）全资子公司云南芙雅生物科技有限公司（以下简称"芙 雅生物"）于近日收到由云南省科学技术厅、云南省财政厅、国家税务总局云南省税务局联合颁发的 《高新技术企业证书》被认定为高新技术企业。证书编号为GR202553000493，有效期三年。 根据国家相关规定，本次通过高新技术企业认定后，芙雅生物将连续三年享受国家关于高新技术企业的 所得税优惠政策，即按15%的税率缴纳企业所得税，本次芙雅生物通过高新技术企业认定事项不会对公 司当期经营业绩产生重大影响。 芙雅生物此次被认定为高新技术企业，有利于进一步提升创新能力、增强市场竞争力。 特此公告 证券代码：603998 证券简称：方盛制药 公告编号：2026-004 湖南方盛制药股份有限公司 关于全资子公司再次被认定为高新技术企业的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司董事会 ...

根据国家相关规定，本次通过高新技术企业认定后，芙雅生 物将连续三年享受国家关于高新技术企业的所得税优惠政策，即 按15%的税率缴纳企业所得税，本次芙雅生物通过高新技术企业 认定事项不会对公司当期经营业绩产生重大影响。 证券代码：603998 证券简称：方盛制药 公告编号：2026-004 湖南方盛制药股份有限公司 关于全资子公司再次被认定为高新技术企业的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）全资子公 司云南芙雅生物科技有限公司（以下简称"芙雅生物"）于近日 收到由云南省科学技术厅、云南省财政厅、国家税务总局云南省 税务局联合颁发的《高新技术企业证书》被认定为高新技术企业。 证书编号为GR202553000493，有效期三年。 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 芙雅生物此次被认定为高新技术企业，有利于进一步提升创 新能力、增强市场竞争力。 特此公告 湖南方盛制药股份有限公司董事会 2026年1月22 ...

根据国家相关规定，本次通过高新技术企业认定后，芙雅生物将连续三年享受国家关于高新技术企业的 所得税优惠政策，即按15%的税率缴纳企业所得税，本次芙雅生物通过高新技术企业认定事项不会对公 司当期经营业绩产生重大影响。 格隆汇1月22日丨方盛制药(603998.SH)公布，公司全资子公司云南芙雅生物科技有限公司于近日收到由 云南省科学技术厅、云南省财政厅、国家税务总局云南省税务局联合颁发的《高新技术企业证书》被认 定为高新技术企业。证书编号为GR202553000493，有效期三年。 ...

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming compared to the ChiNext and CSI 300 indices, ranking 17th among all industries [2][36] - The report emphasizes the importance of innovation, international expansion, and overcoming challenges as key themes for investment in 2026, with a focus on BD 2.0, small nucleic acids, and supply chain opportunities [3][4] - The upcoming adjustment of the National Essential Drug List is seen as critical, aiming to address clinical needs that have evolved since the last update in 2018, particularly in pediatrics, oncology, and rare diseases [5][14] Summary by Sections National Essential Drug List Adjustment Analysis - The current drug list has not been updated since 2018, leading to a disconnect with clinical needs, necessitating a systematic adjustment [14] - The adjustment will focus on filling gaps in disease coverage, particularly in pediatrics, oncology, and rare diseases, while also solidifying the integration of collective procurement and national negotiation outcomes [18][19] - The report identifies potential beneficiaries in traditional Chinese medicine, particularly in areas with previously weak coverage [28] JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline advancements and key clinical milestones for 2026 [33] - Companies like Pfizer, Merck, and Eli Lilly presented their focus on innovative treatments and upcoming clinical trials, indicating a robust pipeline for future growth [34][35] Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance in early 2026 has shown a 7.08% increase, outperforming both the CSI 300 and ChiNext indices [36] - The report notes a shift in market sentiment, with certain innovative sectors like AI healthcare and medical robotics showing strong performance, while traditional sectors faced adjustments [2][3]

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming both the ChiNext Index and the CSI 300 Index, ranking 17th among all industries [2][36] - The report emphasizes a positive outlook for innovation, international expansion, and turnaround opportunities in the pharmaceutical industry, with a focus on BD 2.0, small nucleic acids, and supply chain [3][4] Summary by Sections 1. National Essential Drug List Adjustment Analysis - The adjustment of the National Essential Drug List is urgent as the current version has not been updated since 2018, leading to a disconnect with current clinical needs [14] - The new adjustments will focus on three main areas: addressing gaps in disease coverage, solidifying the integration of centralized procurement and national negotiation results, and enhancing the evidence-based standards for traditional Chinese medicine [5][14] - Potential beneficiaries from the adjustments include companies like Panlong Pharmaceutical, Guizhou Sanli, and Yiling Pharmaceutical, particularly in pediatrics, orthopedics, and cardiovascular fields [5][28] 2. JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline progress and key clinical milestones for 2026 [33] - Companies such as Pfizer, Merck, and Eli Lilly presented their focus on advancing clinical trials and launching new products in various therapeutic areas [34][35] 3. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance from January 12 to January 16 showed a decrease of 0.68%, with a total trading volume of 916.83 billion yuan, accounting for 5.35% of the total market [2][36] - The report notes that the sector has shown a year-to-date increase of 7.08%, outperforming both the CSI 300 and ChiNext indices [36]

Core Viewpoint - The innovative traditional Chinese medicine "Yangxue Qufeng Zhitong Granules," developed by Guang Dong Fangsheng Jianmeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Hunan Fangsheng Pharmaceutical Co., Ltd., has been successfully included in the Guangzhou Innovation Drug and Medical Device Product Directory [1] Company Summary - Hunan Fangsheng Pharmaceutical Co., Ltd. has a subsidiary named Guang Dong Fangsheng Jianmeng Pharmaceutical Co., Ltd. that focuses on the development of innovative traditional Chinese medicine [1] - The company has achieved a significant milestone with its product being recognized in a prominent innovation directory, indicating potential growth and recognition in the pharmaceutical industry [1] Industry Summary - The event held in Huangpu District, Guangzhou, focused on the high-quality development of the biopharmaceutical and health industry, highlighting the importance of innovation in this sector [1] - The inclusion of the product in the innovation directory reflects the growing emphasis on innovative healthcare solutions within the biopharmaceutical industry in Guangzhou [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998) has received a notice from the Hunan Provincial Drug Administration regarding non-compliance in a GMP inspection of its production site for the active pharmaceutical ingredient Indobufen, which is currently in the pre-market preparation stage [1] Group 1: Inspection Results - The inspection conducted in November 2025 concluded that the production site in the Wangcheng Economic Development Zone did not meet the required standards due to outdated production standards for intermediate 1 [1] - The inspection specifically focused on the production line for Indobufen and related processes [1] Group 2: Regulatory Approval and Market Readiness - Indobufen received approval for market launch in June 2024, but the product has not yet been officially released for sale [1] - The company is in the process of rectifying the issues identified during the inspection and plans to reapply for the inspection promptly [1]